Introduction
============

Ovarian epithelial cancer (OEC) is the fourth leading cause of female cancer death in the developed world [@B1], with 50% of all cases occurring in women older than 65 years [@B2]. Ovarian epithelial cancers account for 75% of all ovarian tumors, and 90-95% of ovarian malignancies. The American Cancer Society estimates a total of 22,240 new cases and attributes 14,070 deaths to the disease in 2018. Ovarian cancer burden in China is relatively stable due to the increased aging population [@B3]. The disease has a low survival rate due to the fact that the majority of patients when first diagnosed are already at an advanced stage of ovarian cancer since symptoms are often not apparent during the early development of it. Surgery followed with platinum-based chemotherapy is the standard treatment. In spite of the great improvement in the current therapeutic approach, the survival rate at 5 years for the whole population of ovarian cancer patients is still low (46.5%), and is even worse (29%) in women with late-stage distant disease diffusion [@B4]. High mortality in ovarian cancer underscores the high demand to reveal underlying molecular mechanisms, and to discover molecular biomarkers for early diagnosis, prevention and target therapy.

Different from ovarian epithelial cancer, low malignant potential (LMP) tumors are a distinct subset of epithelial tumor with behavior characteristics in between benign and malignant tumors, and make up approximately 15% of all epithelial ovarian tumors [@B5]. As abnormal cells form in the tissue covering the ovary and do not usually grow into the stroma, LMP tumors are also called borderline malignant ovarian cancer. LMP tumors, which most often affect younger women, display atypical nuclear structure and metastatic behavior, but are considered noninvasive with 5-year survival rates greater than 95% in contrast to a \<45% survival for advanced high-grade OEC [@B6], [@B7].

In the past two decades, about twenty microarray-based gene profiles were performed to seek new insights for biomarkers of ovarian cancers [@B8]. They focused on the prognostic value of gene expression signatures and made advances in disease stratification and prognosis prediction. However, the results were generated from an individual cohort, and were always inconsistent in independent studies. The genetic mechanisms of OEC are far from being understood. An integrated bioinformatics method combined with gene expression profiling will be important to discover more reliable biomarkers for ovarian epithelial cancer.

In this study, the screening of differentially expressed genes between ovarian low malignant potential tumors and ovarian malignant tumors in two individual gene expression datasets were performed, and subsequent analysis of gene ontology, signaling pathway enrichment and protein-protein interaction (PPI) network were carried out. We proposed novel biomarkers for further study.

Materials and Methods
=====================

Gene Datasets
-------------

Two gene expression datasets (GSE9891, GSE12172) were obtained from NCBI Gene Expression Omnibus (GEO) database, available at <http://www.ncbi.nlm.nih.gov/geo/>. GSE9891 comprises molecular profiling from 285 ovarian samples, which include 18 ovarian low malignant potential tumors and 267 malignant ovarian cancers. GSE12172 includes the expression profile of 30 low malignant potential tumors and 60 ovarian malignant serous tumors that originated from ovary epithelial tissue. The experiments of both datasets were performed in Affymetrix Human Genome U133 Plus 2.0 Array microarray platform.

Data Preprocessing and Differentially Expressed Genes (DEGs) Analysis
---------------------------------------------------------------------

By using the robust multi array average (RMA) [@B9] algorithm in R affy package, the raw array data was converted into expression values, and subsequently background correction, quintile normalization and probe summarization were performed. Differentially expressed genes between low malignant potential tumors and malignant ovarian cancers were analyzed by paired t-test based on the limma package in R language. The adjustment of raw *p*-value to false discovery rate (FDR) was carried out by the Benjamini & Hochberg method [@B10]. FDR \< 0.01 and \|log~2~FC\| \> 1.5 were considered as the cutoff value for DEGs screening.

Gene ontology and signaling pathway enrichment analysis of DEGs
---------------------------------------------------------------

Gene ontology analysis (GO) and functional enrichment of the DEGs in the molecular function, biological process and cellular component categories were performed with DAVID, Panther (<http://www.pantherdb.org/>) [@B11] and GO (<http://geneontology.org/>) [@B12] online database. KEGG PATHWAY (<http://www.genome.jp/kegg>) and Reactome (<http://www.reactome.org>) databases were used to perform signaling pathway enrichment analysis with *p* \< 0.05 as a cut-off criterion.

Construction of the PPI network and module analysis
---------------------------------------------------

The interactions between the proteins translated from the identified DEGs were searched by STRING Database (<http://www.string-db.org/>, version 10.5) [@B13], and a confidence score \> 0.4 was used as cut-off criterion. Then cytoscape software (<http://www.cytoscape.org/>) [@B14] was used to visualize the PPI network. Cluster analysis of the PPI network was performed by CFinder (<http://www.cfinder.org/>) [@B15].

CFinder is based on the Clique Percolation Method algorithm to locate the k-clique communities of networks, where k refers to the number of nodes in the subgraph [@B16]. k is the size of the complete subgraphs whose large scale organizations are analytically and numerically investigated. A k-cliques value of \> 10 was selected as the cut-off criterion. Pathway enrichment analysis of two selected modules was performed with a cut-off of *p* \< 0.05.

Results
=======

Identification of DEGs
----------------------

795 DEGs were screened in GSE9891 database, which include 404 up-regulated genes and 391 down-regulated ones.724 DEGs were screened in GSE12172 database, which include 340 up-regulated genes and 384 down-regulated ones. Among these two databases, there are total 559 genes (251 up-regulated and 308 down-regulated) that overlapped (Figure [1](#F1){ref-type="fig"}A, B).

DEGs Gene Ontology Analysis
---------------------------

Three groups of DEGs: molecular function, biological process and cellular component were classified by gene ontology (GO) analysis (Figure [2](#F2){ref-type="fig"}). Among these GO functions, cellular process (GO:0009987), cell part (GO:0044464), binding (GO:0005488), metabolic process (GO:0008152) and biological regulation (GO:0065007) were the top five ones involved in ovarian cancer. Up-regulated genes were mainly enriched in CXCR3 chemokine receptor binding, immune response, chemokine-mediated signaling pathway, chemokine activity, positive regulation of cAMP metabolic process, transcriptional activator activity, RNA polymerase II core promoter proximal region sequence-specific binding and sequence-specific DNA binding (Table [1](#T1){ref-type="table"}). Down-regulated genes were mainly enriched in microtubule, microtubule motor activity, dynein complex, nucleoside kinase activity and nucleoside diphosphate kinase activity (Table [2](#T2){ref-type="table"}).

Signaling Pathway Enrichment Analysis
-------------------------------------

Based on KEGG and Reactome databases, the top five enriched pathways of up-regulated genes were related to Chemokine receptors bind chemokines, G alpha (i) signalling events, Chemokine signaling pathway, Cytokine-cytokine receptor interaction and Mitotic Prometaphase (Table [3](#T3){ref-type="table"}). *ACKR2, CCL11, CDCA8, CENPE, CXCL10, CXCL11, CXCL13, CXCL14, CXCL9, GNGT1, GPR17, NPW, NUF2, PDYN, PTGER3, SKA1, SPC25* and*TNFRSF17* were the genes involved in these five signaling pathways. The most significant enriched pathway in down-regulated genes was Interconversion of nucleotide di- and triphosphates, involving *AK7*, *AK9* and *AK8* (Table [3](#T3){ref-type="table"}).

Analysis of PPI network and modules
-----------------------------------

A total of 282 DEGs of the 559 commonly changed DEGs were screened into the DEGs PPI network complex, containing 282 nodes and 652 edges (Figure [3](#F3){ref-type="fig"}). Using CFinder with a k-cliques value of \> 10, two modules, including module 1 (Figure [4](#F4){ref-type="fig"}A) and module 2 (Figure [4](#F4){ref-type="fig"}B) were extracted from the constructed PPI network. Pathway enrichment analysis showed that Module 1 consisted of 12 nodes and 66 edges (Figure [4](#F4){ref-type="fig"}A, Table [4](#T4){ref-type="table"}), which are mainly associated with G-protein coupled receptor signaling pathway, CXCR3 chemokine receptor binding and CXC chemokine, and that Module 2 consisted of 10 nodes and 45 edges (Figure [4](#F4){ref-type="fig"}B, Table [5](#T5){ref-type="table"}), which are mainly associated with mitotic cell cycle process, nuclear division and chromosome segregation.

Discussion
==========

Invasiveness is one of the aggressive features of ovarian epithelial cancer, in particular the advanced high-grade disease. In contrast, the low malignant potential tumor behaves as a located lesion within the tissue covering the ovary. Characterizing the molecular difference between LMP tumor and OEC will shed light on the mechanism controlling the invasive trait of OEC malignances. In the present study, we integrated two individual cohorts of profile datasets, and used multiple bioinformatics tools to identify significant genes and pathways between LMP tumors and ovarian epithelia cancers. A total of 559 differentially expressed genes were screened in two public available GEO datasets, including 251 up-regulated and 308 down-regulated genes. Based on the gene ontology analysis, a greater majority of the DEGs were involved in biological process, specifically the cellular process, than in cellular component or molecular function (Figure [2](#F2){ref-type="fig"}). GO function analysis revealed that more significant enrichments in the up-regulated DEGs were CXCR3 chemokine, immune response and chemokine-mediated signaling pathway.

Through literature survey, we found that the increased expression and release of pro-inflammatory chemokines have been associated with progression of ovarian cancer, which may induce tumor cell proliferation, survival, migration, and angiogenesis [@B17]-[@B19]. The enrichments of chemokine and immune response pathway in this study highly validated their important roles in OEC malignancies. Consistent with Gene Ontology analysis, signaling pathway enrichment analysis displayed the same signaling pathways in the up-regulated DEGs: Chemokine receptors bind chemokines, G alpha (i) signaling events, Chemokine signaling pathway and Cytokine-cytokine receptor interaction. Chemokines are a family of cytokines that induce chemotaxis of target cells and bind to the G protein coupled chemokine receptors. Other than the function of inducing leukocyte migration (including dendritic cells, macrophages, and neutrophils) into the infected or injured sites [@B20], they can promote cancer progression [@B21]-[@B25].

GO analysis in down-regulated DEGs showed that more significant enrichments were microtubule, microtubule motor activity, dynein complex and microtubule-based movement. All of these enrichments were associated with microtubule function. Microtubules are highly dynamic structures that play an important role in cellular growth, vesicular transport and mitosis [@B26]. They are composed of α/β-tubulin heterodimers [@B27]. Alterations in specific β-tubulin isotypes in epithelial cancers are associated with resistance to tubulin-binding agent chemotherapy and more aggressive disease [@B28]. Microtubules were linked in tumor cell migration and metastasis [@B26].

More interestingly, 12 genes were selected in the most significant k-clique module 1 of the PPI network: *APLNR*, *CNR1*, *CXCL9*, *CXCL10*, *CXCL11*, *CXCL13*, *GNGT1*, *GPR17*, *GRM7*, *NPW*, *PDYN*, *PTGER3*. Among them, most genes were chemokines and involved cancer immunity. *APLNR* is a member of G-protein coupled receptor signaling pathway, which was significantly mutated in human cancers [@B29]. APELA, the ligand of APLNR, can promote ovarian cancer cell growth and migration [@B30]. *CNR1* gene expression was down-regulated in endometrial carcinomas, another gynecologic cancer which was validated by qRT-PCR [@B31]. Inversely, Messalli et al. found that expression of CB1R (alias of CNR1) increased from benign and borderline to malignant tumors by immunohistochemical quantification [@B32]. A possible reason for the discrepancy between gene and protein expression is that other post-transcription and/or post-translation mechanisms affect CNR1 expression. *CXCL9* and *CXCL10* expression was associated with improved patient survival, and these two chemokines were synergistically induced by inflammatory cytokines [@B33]. *CXCL11* promoted proliferation and migration of ovarian cancer cells via the chemokine receptor CXCR3, thus CXCL11-CXCR3 signaling represented therapeutic targets in ovarian cancer [@B34]. In independent cohorts of ovarian cancer patients, high *CXCL13* correlated strongly with better prognosis [@B35]. Based on the function of uncovered genes, we hypothesized, *GNGT1*, *GPR17*, *GRM7*, *NPW*, *PDYN* and *PTGER3* can influence OEC development via chemokine signaling.

In module 2, *ASPM*, *CDCA8*, *CENPE*, *EXO1*, *FOXM1*, *MCM10*, *NCAPH*, *NUF2*, *SKA1* and *SPC25* were displayed and mainly associated with mitotic cell cycle. Most of these genes were studied and identified in ovarian cancers. Deregulation of *ASPM* in OEC correlates with tumor progression, grade and survival [@B36], [@B37]. *CDCA8* was significantly higher in ovarian cancer cells compared with ovarian epithelial cells by using quantitative PCR with reverse transcription analysis [@B38]. *CENPE*, a cell cycle regulating gene, was up-regulated in chemo-resistant ovary tumors [@B39]. CENPE proteins were significantly up-regulated in the fibroblasts co-cultured with ovarian cancer cells [@B40]. Attenuating *EXO1* expression by small interfering RNA augments the chemotherapy efficacy against ovarian cancer [@B41]. *FOXM1* acted as a transcriptional activator involved in cell proliferation to promote cell cycle progression in OEC cells [@B42]. *NUF2* was significantly aberrantly overexpressed in ovary serous adenocarcinomas, and silencing of *NUF2* induced increased apoptosis [@B43]. It is speculated that the undiscovered four genes (*MCM10*, *NCAPH*, *SKA1*, *SPC25*) involved in cell cycle may exert effects in OEC.

Taken together, chemokine-related signaling, mitotic cell cycle and microtubule pathways play important roles in pathogenesis and aggressiveness of ovarian epithelial cancer. Nine novel up-regulated genes (*GNGT1*, *GPR17*, *NPW*, *PDYN*, *PTGER3*, *MCM10*, *NCAPH*, *SKA1*, *SPC25*) and one down-regulated gene (*GRM7*) are linked with OEC invasiveness. This is the first time the identified genes from this study have been proposed, but these results will require confirmation through further studies.
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![**Identification of 559 commonly changes DEGs from the two profile datasets (GSE9891, GSE12172).** Different color areas represented different datasets. The cross areas meant the commonly changed DEGs. DEGs were identified with t-test, statistically significant DEGs were defined with *p*\<0.05 and \[log~2~FC\]\>1.5 as the cut-off criterion.](jcav09p3016g001){#F1}

![**Gene Ontology analysis of DEGs in ovarian cancer.** GO analysis classified the DEGs into 3 groups: molecular function, biological process and cellular component.](jcav09p3016g002){#F2}

![**DEGs protein-protein interaction network complex.** Total of 282 DEGs were screened into, containing 282 nodes and 652 edges.](jcav09p3016g003){#F3}

![**Two most significant k-clique modules in the PPI network. (A)** Module 1 consisted of 12 nodes and 66 edges, which are mainly associated with G-protein coupled receptor signaling pathway, CXCR3 chemokine receptor binding and CXC chemokine; **(B)** Module 2 consisted of 10 nodes and 45 edges, which are mainly associated with mitotic cell cycle process, nuclear division and chromosome segregation. Genes in red represent as upregulation and genes in green represent as downregulation.](jcav09p3016g004){#F4}

###### 

Significant enriched GO terms of up-regulated DEGs in ovarian cancer

  Term name                    Description                                                                                                     Count   *p*-value
  ---------------------------- --------------------------------------------------------------------------------------------------------------- ------- -----------
  **Enrichment Score: 2.46**                                                                                                                           
  GO:0048248                   CXCR3 chemokine receptor binding                                                                                4       1.49E-05
  GO:0006955                   immune response                                                                                                 17      2.97E-05
  GO:0070098                   chemokine-mediated signaling pathway                                                                            7       1.64E-04
  GO:0008009                   chemokine activity                                                                                              6       2.47E-04
  GO:0030816                   positive regulation of cAMP metabolic process                                                                   3       0.00191
  GO:0043950                   positive regulation of cAMP-mediated signaling                                                                  3       0.00804
  GO:0007267                   cell-cell signaling                                                                                             9       0.00918
  GO:0006935                   chemotaxis                                                                                                      6       0.01338
  GO:0002690                   positive regulation of leukocyte chemotaxis                                                                     3       0.01781
  GO:0051281                   positive regulation of release of sequestered calcium ion into cytosol                                          3       0.03821
  GO:0032496                   response to lipopolysaccharide                                                                                  6       0.04135
  **Enrichment Score: 2.06**                                                                                                                           
  GO:0001077                   transcriptional activator activity, RNA polymerase II core promoter proximal region sequence-specific binding   12      9.65E-05
  GO:0043565                   sequence-specific DNA binding                                                                                   17      3.48E-04
  GO:0045944                   positive regulation of transcription from RNA polymerase II promoter                                            22      0.00447
  GO:0000978                   RNA polymerase II core promoter proximal region sequence-specific DNA binding                                   11      0.00836
  GO:0006366                   transcription from RNA polymerase II promoter                                                                   13      0.01569
  GO:0003700                   transcription factor activity, sequence-specific DNA binding                                                    17      0.09053

###### 

Significant enriched GO terms of down-regulated DEGs in ovarian cancer

  Term name                    Description                                            Count   *p*-value
  ---------------------------- ------------------------------------------------------ ------- -----------
  **Enrichment Score: 3.67**                                                                  
  GO:0005874                   microtubule                                            17      1.12E-06
  GO:0003777                   microtubule motor activity                             9       3.62E-06
  GO:0030286                   dynein complex                                         6       5.22E-06
  GO:0007018                   microtubule-based movement                             7       3.48E-04
  GO:0016887                   ATPase activity                                        7       0.01885
  **Enrichment Score: 1.80**                                                                  
  GO:0019206                   nucleoside kinase activity                             3       0.00550
  GO:0004550                   nucleoside diphosphate kinase activity                 3       0.02158
  GO:0015949                   nucleobase-containing small molecule interconversion   3       0.03346

###### 

Signaling pathway enrichment analysis of DEGs function in ovarian cancer

  Pathway                  Name                                                  Count   *p*-value   Genes
  ------------------------ ----------------------------------------------------- ------- ----------- ----------------------------------------------------------------
  **Up-regulated DEG**                                                                               
  R-HSA-380108             Chemokine receptors bind chemokines                   6       5.26E-04    CCL11, CXCL13, CXCL9, ACKR2, CXCL11, CXCL10
  R-HSA-418594             G alpha (i) signaling events                          9       0.00675     GNGT1, PTGER3, CXCL13, NPW, CXCL9, GPR17, PDYN, CXCL11, CXCL10
  KEGG: hsa04062           Chemokine signaling pathway                           7       0.01032     CCL11, GNGT1, CXCL14, CXCL13, CXCL9, CXCL11, CXCL10
  KEGG: hsa04060           Cytokine-cytokine receptor interaction                7       0.02668     CCL11, CXCL14, CXCL13, CXCL9, TNFRSF17, CXCL11, CXCL10
  R-HSA-68877              Mitotic Prometaphase                                  5       0.03419     SPC25, CDCA8, NUF2, CENPE, SKA1
  R-HSA-2500257            Resolution of Sister Chromatid Cohesion               5       0.04855     SPC25, CDCA8, NUF2, CENPE, SKA1
  **Down-regulated DEG**                                                                             
  R-HSA-499943             Interconversion of nucleotide di- and triphosphates   3       0.01646     AK7, AK9, AK8

###### 

Top 10 of pathway enrichment analysis of Module 1 genes function

  Category        Term name    Description                                                 Count   *p*-value
  --------------- ------------ ----------------------------------------------------------- ------- -----------
  GO Process      GO:0007186   G-protein coupled receptor signaling pathway                11      7.03E-10
  GO Function     GO:0048248   CXCR3 chemokine receptor binding                            4       1.40E-09
  InterPro        IPR001089    CXC chemokine                                               4       2.73E-08
  InterPro        IPR018048    CXC chemokine, conserved site                               4       2.73E-08
  GO Process      GO:0070098   chemokine-mediated signaling pathway                        5       1.36E-07
  GO Process      GO:0048247   lymphocyte chemotaxis                                       4       9.50E-07
  InterPro        IPR001811    Chemokine interleukin-8-like domain                         4       1.05E-06
  Pfam            PF00048      Small cytokines (intecrine/chemokine), interleukin-8 like   4       1.48E-06
  GO Process      GO:0032496   response to lipopolysaccharide                              6       9.96E-06
  KEGG Pathways   04062        Chemokine signaling pathway                                 5       1.02E-05

###### 

Top 10 of pathway enrichment analysis of Module 2 genes function

  Category       Term name    Description                                Count   *p*-value
  -------------- ------------ ------------------------------------------ ------- -----------
  GO Process     GO:1903047   mitotic cell cycle process                 9       3.82E-09
  GO Process     GO:0007049   cell cycle                                 10      3.82E-09
  GO Process     GO:0000278   mitotic cell cycle                         9       6.37E-09
  GO Process     GO:0007067   mitotic nuclear division                   7       7.95E-08
  GO Process     GO:0007059   chromosome segregation                     6       2.14E-07
  GO Process     GO:0051301   cell division                              7       4.07E-07
  GO Component   GO:0000793   condensed chromosome                       5       8.13E-06
  GO Component   GO:0000775   chromosome, centromeric region             5       8.13E-06
  GO Component   GO:0000777   condensed chromosome kinetochore           4       4.33E-05
  GO Component   GO:0000779   condensed chromosome, centromeric region   4       4.33E-05
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